Bayer AG has taken steps to expand its portfolio of medicines for gynaecological diseases with the acquisition of UK-based KaNDy Therapeutics Plc and its non-hormonal compound, NT-814, for the treatment of the symptoms of menopause. The acquisition complements Bayer’s existing portfolio of birth control treatments, as well as therapies for management of the menopause.
KaNDy Therapeutics was founded in 2017 with financial support Advent Life Sciences, Forbion Capital Partners and OrbiMed, among others. NT-814, the company’s main asset,